ARTICLE | Product R&D

Making cells compute

The momentum is building in synthetic biology; CAR Ts stand to benefit

May 18, 2017 11:07 PM UTC

With efficiency in DNA engineering continuing to grow, and an increasing convergence between engineering and biology, synthetic biology -- in its “truest” form -- is coming within striking distance of translating preclinical proof of concept breakthroughs to the clinic.

And while chimeric antigen receptor (CAR) T cells could be prime beneficiaries of the advances, some basic tenets of the technology might present IP lawyers with new challenges. ...